dIgA Assays for SARS-CoV-2 Infection Timing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting recent SARS-COV-2 infections and assessing immune responses are hindered by high false-positive rates in IgM assays and the inability to distinguish between recent and distant infections, particularly in low-prevalence settings, and fail to accurately measure mucosal immune responses due to the dominance of monomeric IgA in circulation.
Innovation Solution
Development of assays and kits that specifically detect dimeric IgA (dIgA) using polymeric Ig receptor (pIgR)-based reagents, such as chimeric secretory component (CSC), to differentiate between recent and less recent infections by measuring antigen-specific dIgA levels in blood, which correlates with mucosal immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If IgM assays are used to detect recent infections, then detection sensitivity for acute infections is improved, but false-positive rates increase significantly
Solution Approach 1:
The invention segments the IgA antibody population into monomeric and dimeric forms, using dIgA as a specific marker for recent infections. This segmentation allows differentiation between recent and distant infections, resolving the contradiction between detection sensitivity and false-positive rates by providing a more specific biomarker.
Solution Approach 2:
The invention uses pIgR-based reagents as intermediaries to specifically detect dimeric IgA. These reagents act as mediators that selectively bind to dIgA, enabling accurate detection of recent infections while avoiding the false positives associated with IgM assays.
2Quantity of substance
If total IgA measurements are used to assess immune responses, then abundance and ease of detection are improved, but ability to measure mucosal immune responses is lost
Solution Approach 1:
The invention segments total IgA into monomeric and dimeric forms, recognizing that dIgA is the precursor to secretory IgA at mucosal surfaces. By measuring dIgA specifically, the invention maintains the advantage of IgA abundance while regaining the ability to accurately assess mucosal immune responses.
Solution Approach 2:
The invention employs pIgR-based reagents as intermediaries that specifically recognize and bind to dimeric IgA. This selective binding enables the measurement of dIgA levels in circulation, providing a proxy for mucosal immune responses while utilizing the ease of blood sampling.
3Ease of operation
If monomeric IgA is measured in circulation, then detection simplicity is improved, but correlation with functional mucosal immunity is reduced
Solution Approach 1:
The invention segments IgA into monomeric and dimeric forms, identifying dIgA as the form that correlates with mucosal immunity. This segmentation maintains operational simplicity through blood sampling while improving the precision of mucosal immune response assessment by targeting the functionally relevant dimeric form.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods provide a reliable and sensitive means to estimate the time since infection and the magnitude of mucosal immune responses, enhancing contact tracing, vaccine efficacy assessment, and convalescent plasma therapy by accurately distinguishing between recent and past infections, and identifying individuals with high neutralizing antibody levels.
Implementation Method 1
assays and kits that specifically detect dimeric IgA (dIgA) using polymeric Ig receptor (pIgR)-based reagents, such as chimeric secretory component (CSC)
Implementation Method 2
measuring antigen-specific dIgA levels in blood
Data Source
AI summary
The present application relates to infectious diseases, pathogenic organisms or pathogenic antigens, and the immune responses that are the body's first line of defense thereto. The application enables medical protocols and products inter alia for treating or preventing or limiting the dissemination of an infectious disease. Methods and compositions are disclosed which employ dIgA for assessing functional immune responses to a pathogen, and in prophylactic or therapeutic compositions. In particular embodiments, the methods and compositions enhance the armamentarium for those charged with managing infectious diseases and populations exposed to highly transmissible and potentially debilitating or fatal pathogens such as those causing epidemics. One particular infectious disease is COVID-19 caused by the virus SARS-COV-2.